Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests Alfacalcidol Does Not Lower CV Risk in Dialysis, Trial Suggests

Alfacalcidol did not reduce the risk for cardiovascular events in patients without secondary hyperparathyroidism who were undergoing maintenance hemodialysis, the J-DAVID trial found.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Nephrology News Source Type: news